Genomic Landscape and Targeted Treatment of Gallbladder Cancer: Results of a First Ongoing Prospective Study

Abstract

Background Prognosis of gallbladder cancer (GBC) has not changed in the past 20 years. Comprehensive genomic profiling (CGP) carries potential to determine the actionability for multiple targets, including ERBB2, ERBB3, MET, ROSI, FGFR, and PIK3. This study evaluates the role of CGP and targeted therapies.

Methods This is a multicenter, prospective, single-arm study. All consecutive patients of unresectable and/or metastatic GBC of age ≥18 years were enrolled. Hybrid capture-based CGP was performed by Foundation Medicine CDx. All patients received first-line chemotherapy with gemcitabine–cisplatin regimen. Patients with ERBB2/3 amplification received trastuzumab with capecitabine or nab-paclitaxel, and patients with MET amplification were treated with crizotinib. For ERBB2/3 mutations, lapatinib plus capecitabine regimen was used.

Results Fifty patients were studied with a median age of 56 years (range 26–83) and a male-to-female ratio of 1:1.6. ERBB2 and ERBB3 amplification was seen in 9 (18%) and 2 (4%) patients, respectively. Four patients with ERBB2 amplification received trastuzumab and/or lapatinib, showed partial response, and maintained response beyond 12 weeks. One patient had mixed response, whereas two patients progressed on trastuzumab and lapatinib. Three patients with ERBB3 mutations showed response to lapatinib–capecitabine. One patient with MET amplification responded to crizotinib for 4 weeks. PIK3 mutations were present in 14% of cases and were independent of ERBB aberrations.

Conclusion GBC is enriched in 28% of patients with ERBB2 and ERBB3 amplifications and/or mutations. Responses are seen with lapatinib in concurrent ERBB2 mutation and amplification. ERBB3 mutation showed response to lapatinib. MET and PIK3 are new findings in GBC, which may be targeted.

Keywords

comprehensive genomic profiling - ERBB2/3 - gallbladder cancer - targeted therapy

Publikationsverlauf

Artikel online veröffentlicht:
14. Dezember 2020

• References

• 1 Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer 2006; 118 (07) 1591-1602
• 2 Malhotra RK, Manoharan N, Shukla NK, Rath GK. Gallbladder cancer incidence in Delhi urban: A 25-year trend analysis. Indian J Cancer 2017; 54 (04) 673-677
• 3 Shukla HS, Sirohi B, Behari A. et al. Indian Council of Medical Research consensus document for the management of gall bladder cancer. Indian J Med Paediatr Oncol 2015; 36 (02) 79-84
• 4 Valle JW, Furuse J, Jitlal M. et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol 2014; 25 (02) 391-398
• 5 Lindnér P, Holmberg E, Hafström L. Gallbladder cancer - no improvement in survival over time in a Swedish population. Acta Oncol 2018; 57 (11) 1482-1489
• 6 ECOG-ACRIN. ECOG Performance Status. Available at: http://ecog-acrin.org/resources/ecog-performance-status. Accessed December 28, 2016
• 7 Li M, Zhang Z, Li X. et al. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. Nat Genet 2014; 46 (08) 872-876
• 8 Mishra R, Hanker AB, Garrett JT. Genomic alterations of ERBB receptors in cancer: clinical implications. Oncotarget 2017; 8 (69) 114371-114392
• 9 Subramanian J, Katta A, Masood A, Vudem DR, Kancha RK. Emergence of ERBB2 mutation as a biomarker and an actionable target in solid cancers. Oncologist 2019; 24 (12) e1303-e1314
• 10 Yi Z, Ma F, Guan Y. et al. Impact of HER2 mutation status on personalized molecular targeted therapy in advanced breast cancers. J Clin Oncol 2018; 36 (Suppl. 15) 1039
• 11 Javle M, Churi C, Kang HC. et al. HER2/neu-directed therapy for biliary tract cancer. J Hematol Oncol 2015; 8: 58
• 12 Li M, Liu F, Zhang F. et al. Genomic ERBB2/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis. Gut 2019; 68 (06) 1024-1033
• 13 Kawakami H, Okamoto I, Okamoto W, Tanizaki J, Nakagawa K, Nishio K. Targeting MET amplification as a new oncogenic driver. Cancers (Basel) 2014; 6 (03) 1540-1552
• 14 Jain A, Borad MJ, Kelley RK. et al. Cholangiocarcinoma with FGFR genetic aberrations: a unique clinical phenotype. JCO Precision Oncol 2018; 2: 1-12
• 15 Ross JS, Wang K, Gay L. et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist 2014; 19 (03) 235-242
• 16 Graham RP, Barr Fritcher EG, Pestova E. et al. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Hum Pathol 2014; 45 (08) 1630-1638
• 17 Javle M, Lowery M, Shroff RT. et al. Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J Clin Oncol 2018; 36 (03) 276-282
• 18 Food and Drug Administration. FDA approves first targeted therapy for metastatic bladder cancer. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-metastatic-bladder-cancer. Accessed August 21, 2019
• 19 André F, Ciruelos E, Rubovszky G. et al. SOLAR-1 Study Group. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med 2019; 380 (20) 1929-1940
• 20 Commissioner of the FDA approves first PI3K Inhibitor for Breast Cancer. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-pi3k-inhibitor-breast-cancer. Accessed February 5, 2020
• 21 Lee H, Ross JS. The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer. Therap Adv Gastroenterol 2017; 10 (06) 507-520
• 22 Neyaz A, Husain N, Kumari S. et al. Clinical relevance of PD-L1 expression in gallbladder cancer: a potential target for therapy. Histopathology 2018; 73 (04) 622-633
• 23 Yang P, Javle M, Pang F. et al. Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients. Hepatobiliary Surg Nutr 2019; 8 (06) 604-614
• 24 Goeppert B, Roessler S, Renner M. et al. Low frequency of mismatch repair deficiency in gallbladder cancer. Diagn Pathol 2019; 14 (01) 36